1,403 Followers on Owler


Read more
Jan Lichtenberg's photo - Co-Founder & CEO of InSphero

Co-Founder & CEO

Jan Lichtenberg

CEO Approval Rating





PrivateIndependent Company

Est. Annual Revenue
Est. Employees









InSphero's company profile
Jan Lichtenberg's photo - Co-Founder & CEO of InSphero

Jan Lichtenberg

Co-Founder & CEO

View Profile
InSphero's Competitor - Synthecon logo
William Anderson's photo - President & CEO of Synthecon

William Anderson

President & CEO

- -
View Profile
InSphero's Competitor - 3D Biotek logo
Wing K. Lau's photo - CEO of 3D Biotek

Wing K. Lau


- -
View Profile
InSphero's Competitor - Aspect Biosystems logo
Tamer Mohamed's photo - President & CEO of Aspect Biosystems

Tamer Mohamed

President & CEO

View Profile
InSphero's Competitor - Nagi Bioscience logo
Matteo Cornaglia's photo - Co-Founder & CEO of Nagi Bioscience

Matteo Cornaglia

Co-Founder & CEO

View Profile
InSphero's Competitor - Ascendance Biotechnology logo
CEO Avatar

Vincent R. Zurawski

Co-Founder & CEO

View Profile

Missing a competitor? Contribute!

Synthecon is the top competitor of InSphero. Synthecon is a Private company that was founded in Houston, Texas in 1990. Like InSphero, Synthecon also operates in the Biotechnology sector. Synthecon has 12 fewer employees vs. InSphero.

3D Biotek is seen as one of InSphero's biggest rivals. 3D Biotek was founded in Bridgewater, New Jersey} in 2007. Like InSphero, 3D Biotek also competes in the Biotechnology space. Compared to InSphero, 3D Biotek generates $4M less revenue.

Aspect Biosystems is perceived as one of InSphero's biggest rivals. Aspect Biosystems was founded in 2013, and is headquartered in Vancouver, British Columbia. Aspect Biosystems operates in the Computers, Peripherals, Networking and Electronic Equipment industry. Aspect Biosystems generates $4M less revenue vs. InSphero.

InSphero Acquisitions

No recent acquisitions found related to InSphero

InSphero Funding History

Since InSphero was founded in 2009, it has participated in 5 rounds of funding. In total InSphero has raised $34.2M. InSphero's last funding round was on Mar 2019 for a total of $0





Mar 2019
Jun 2018
Oct 2015
Series C
Jul 2015
Series B
Jun 2013

Since InSphero was founded in 2009, it has participated in 5 rounds of funding. In total InSphero has raised $34.2M. InSphero's last funding round was on Mar 2019 for a total of $0

InSphero Investments

No recent investments found related to InSphero

InSphero News

August 5, 2020startupticker ch

Insphero among Red Dot's Best of the Best Award winners

Swiss startup Insphero has received the Red Dot Award for its revolutionary new transport technology,... See more »
November 6, 2019MarketScreener

InSphero joins Science Exchange Network to Offer Expanded Online Access to 3D InSight Microtissue Technology and Services

(marketscreener.com) R&D services platform will make it easier for researchers throughout the world t... See more »
October 3, 2019BioSpace

Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight Human Liver Disease platform

3D InSight Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-001 ... See more »
October 3, 2019firstwordpharma

Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight Human Liver Disease platform

SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ -- Akero Therapeutics and InSpher... See more »
December 19, 20184-traders

InSphero and Path BioAnalytics Announce Partnership to Develop Advanced 3D Airway Tissue Model for Cystic Fibrosis Research

(marketscreener.com) Schlieren, Switzerland, Dec. 19, 2018 (GLOBE NEWSWIRE) -- InSphero AG and Path B... See more »
October 11, 2018Benzinga

InSphero achieves new milestone with Akura Flow organ-on-a-chip technology in low-clearance drug study

Schlieren, Switzerland, Oct. 11, 2018 (GLOBE NEWSWIRE) -- InSphero AG today announced that it has suc... See more »
September 30, 2018BioPortfolio

InSphero AG Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250

SummaryInSphero AG InSphero is a biotechnology company that offers production culture and assessment ... See more »

InSphero Blogs

July 2, 2020InSphero Blog

A Novel Hanging Drop Organ-on-a-Chip System for Diabetes Drug Discovery

InSphero has a rich history of collaborating with researchers at ETH Zürich. The most recent example ... See more »
June 12, 2020InSphero Blog

Understanding Microfluidics: Toward Scalable Body-on-a-Chip Systems

Microfluidics expert Olivier Frey explains how higher-order systems, such as multi-tissue Body-on-a-C... See more »
May 1, 2020InSphero Blog

The Future of High Content Analysis is 3D

InSphereo recently had an opportunity to test the Yokogawa platform for High Content Analysis (HCA) i... See more »
May 1, 2020InSphero Blog

Experimental Design Considerations for NASH Drug Screening

An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for pre... See more »
March 13, 2020InSphero Blog

InSphero launches new webinar series, starting with virtual SOT 2020 sessions

As the coronavirus epidemic prompts cancellations of scientific meetings around the world, we have be... See more »
February 26, 2020InSphero Blog

Are I-O therapeutics making traditional in vitro assays obsolete or is it time to reinvent the testing tree?

InSphero Oncology Expert Irina Agarkova shares her thoughts on how the rapidly changing field of immu... See more »
December 18, 2019InSphero Blog

InSphero marks 10 years of Innovation in 3D cell-based assay technology

InSphero CEO Jan Lichtenberg muses about how far 3D cell technology has come since InSphero was found... See more »

InSphero Press Releases

June 11, 2018streetinsider

InSphero Partners with ALPCO to Advance Diabetes Research

InSphero AG, the leading provider of 3D cell-based platforms for preclinical drug safety and efficacy... See more »
April 18, 2017Marketwired

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

Establishing standards for next-generation tumor models to benefit drug discovery and broader researc... See more »
April 3, 2017Blackbird

Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies

InSphero presents latest data demonstrating immune cell interaction with 3D tumor models for in vitro... See more »
November 3, 2016Marketwired

InSphero Scientist Receives 3Rs Award for Microtissue-based Body on a Chip System

Dr. Olivier Frey honored by IQ Consortium and AAALAC International for work on microphysiological sys... See more »
October 19, 2016Marketwired

3D Cell Culture Experts Assemble for Inaugural New Frontiers in 3D Conference

Event draws over 100 leading government, industry, and academic leaders to further translational appl... See more »

InSphero Videos

Social Media

InSphero Headquarters

Wagistrasse 27A

Schlieren, Zurich8952


Driving Directions »

Trending Companies

InSphero Summary



InSphero is a provider of 3-Dimensional tissue-based assay solutions for pharmaceuticals, cosmetics and biotechnology industries. InSphero was founded in 2009. InSphero's headquarters is located in Schlieren, Zurich, CH 8952. It has raised 34.2M in 5 ...


InSphero's Co-Founder & CEO, Jan Lichtenberg, currently has an approval rating of 99%. InSphero's primary competitors are Synthecon, 3D Biotek & Aspect Biosystems.

Frequently Asked Questions about InSphero

  1. When was InSphero founded?

    InSphero was founded in 2009
  2. Who is InSphero's CEO?

    InSphero's CEO is Jan Lichtenberg
  3. How much revenue does InSphero generate?

    InSphero generates $9M in revenue
  4. How much funding does InSphero have?

    InSphero has historically raised $34.2M in funding
  1. Where is InSphero's headquarters?

    InSphero's headquarters is in Schlieren Zurich, CH
  2. How many employees does InSphero have?

    InSphero has 60 employees
  3. What sector does InSphero operate in?

    InSphero is in Biotechnology
  4. Who are InSphero's competitors?

    InSphero's top competitors are Synthecon, 3D Biotek, Aspect Biosystems